Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia

References

• Kantarjian H, Giles F J, O'Brien S M, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematology Oncology Clinics of North America 1998; 12: 31–79
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J L, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall J F, Tanzer J, French Chronic Myeloid Leukemia Study Group. Interferon-alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Smith T L, Rios M B, Cortes J, Beran M, Koller C, Giles F J, Andreeff M, Kornblau S, Giralt S, Keating M, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytosine arabinoside. J Clin Oncol 1999; 17: 284–292
   PubMed Web of Science ®Google Scholar
• Huang M E, Ye Y C, Chen S R, Chai J R, Jia-Xiang L, Lin Z, Long-Jun G, Zhenyi W. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti M C, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398
   PubMed Web of Science ®Google Scholar
• Sacchi S, Russo D, Avvisati G, Dastoli G, Lazzarino M, Pelicci P G, Bonora M R, Visani G, Grassi C, Lacona I, Luzzi L, Vanzanelli P. All-trans retinoic acid in hematological malignancies, an update. Haematologica 1997; 82: 106–121
   PubMed Web of Science ®Google Scholar
• Gallagher R, Ahearn G, Thompson D, Streck M, Paietta E, Dutcher J, Wiernik P. Retinoic acid enhanced neutrophilic differentiation of granulocyte-macrophage progenitors in blastic crisis chronic myelogenous leukemia. Blood 1990; 76: 272a
   Google Scholar
• Januszewicz E, Rabizadah E, Maimon Z, Zaizof R, Shaklai M. Inhibition by retinoic acid of myeloid progenitors in chronic myeloid leukemia and myeloproliferative diseases: increased sensitivity in blast phase of chronic myeloid leukemia. Pathology 1988; 20: 1–6
   PubMed Web of Science ®Google Scholar
• Sagayadan G E, Peter H, Wiernik P H, Sun N, Ahern G, Thompson D, Hallam S J, Hu X P, Dutcher J P, Gallagher R E. Effect of retinoid acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans and 13-cis-retinoic acid in advanced stage disease. Leukemia Res 1994; 18: 741–748
   PubMed Web of Science ®Google Scholar
• Aglietta M, Piacibello W, Stacchini A, Sanavio E, Gavosto F. In vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. Leukemia Res 1985; 9: 879–883
   PubMed Web of Science ®Google Scholar
• Nilsson B, Olofssson T, Olsson I. Myeloid differentiation in liquid cultures of cells from patients with chronic myeloid leukemia: effects of retinoic acid and indomethacin. Exp Hematol 1984; 12: 91–99
   PubMed Web of Science ®Google Scholar
• Moore M, Mertelsmann R, Pelus I. Phenotypic evaluation of chronic myeloid leukemia. Blood Cells 1981; 7: 217–236
   PubMedGoogle Scholar
• Zheng A, Savolainen E R, Koistinen P. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. Leukemia Res 1996; 20: 243–248
   PubMed Web of Science ®Google Scholar
• Guglielmo P, Stagno F, Cacciola E, Jr, Cacciola R R, Impera S, Giustolisi R, Cacciola E. All-trans retinoic acid (ATRA) induced apoptosis in peripheral freshly isolated chronic myeloid leukemia cells. Blood 1995; 86(Suppl 1)253a, Leukemia
   Google Scholar
• Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia 1997; 11: 929–932
   PubMed Web of Science ®Google Scholar
• Russo D, Regazzi M, Sacchi S, Visani G, Lazzarino M, Avvisati G, Pelicci P G, Dastoli G, Grandi C, Lacona I, Candoni A, Grattoni R, Galieni P, Rupoli S, Liberati A M, Maiolo A T. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. Leukemia 1998; 12: 449–454
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: A concise update. Blood 1993; 82: 691–703
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 1988
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemoter Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Kantarjian H M, Keating M J, Smith T L, Talpaz M, McCredie K B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990; 88: 1–8
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Corso A, Regazzi M B, Lacona I, Bernasconi C. Modulation of all-trans retinoic acid pharmacokinetics in acute promyelocytic leukaemia by prolonged interferon-α therapy. Brit J Haemat 1995; 90: 928–930
   PubMed Web of Science ®Google Scholar